These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 17030015

  • 1. Involvement of insulin-like growth factor-I in the control of glucose homeostasis.
    Clemmons DR.
    Curr Opin Pharmacol; 2006 Dec; 6(6):620-5. PubMed ID: 17030015
    [Abstract] [Full Text] [Related]

  • 2. Role of insulin-like growth factor iin maintaining normal glucose homeostasis.
    Clemmons DR.
    Horm Res; 2004 Dec; 62 Suppl 1():77-82. PubMed ID: 15761237
    [Abstract] [Full Text] [Related]

  • 3. Does recombinant human insulin-like growth factor-1 have a role in the treatment of diabetes?
    Dunger DB, Acerini CL.
    Diabet Med; 1997 Sep; 14(9):723-31. PubMed ID: 9300221
    [Abstract] [Full Text] [Related]

  • 4. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E, Minuto F, Colao A, Ferone D.
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [Abstract] [Full Text] [Related]

  • 5. Free insulin-like growth factors -- measurements and relationships to growth hormone secretion and glucose homeostasis.
    Frystyk J.
    Growth Horm IGF Res; 2004 Oct; 14(5):337-75. PubMed ID: 15336229
    [Abstract] [Full Text] [Related]

  • 6. Treatment with insulin glargine does not suppress serum IGF-1.
    Slawik M, Schories M, Busse Grawitz A, Reincke M, Petersen KG.
    Diabet Med; 2006 Jul; 23(7):814-7. PubMed ID: 16842489
    [Abstract] [Full Text] [Related]

  • 7. The effects of the insulin-like growth factor-I aptamer, NBI-31772, on glucose homeostasis in the mouse.
    Silha JV, Murphy LJ.
    Can J Physiol Pharmacol; 2005 Jul; 83(7):557-63. PubMed ID: 16091781
    [Abstract] [Full Text] [Related]

  • 8. Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose.
    Clemmons DR, Moses AC, Sommer A, Jacobson W, Rogol AD, Sleevi MR, Allan G.
    Growth Horm IGF Res; 2005 Aug; 15(4):265-74. PubMed ID: 16005252
    [Abstract] [Full Text] [Related]

  • 9. Therapeutic aspects of growth hormone and insulin-like growth factor-I treatment on visceral fat and insulin sensitivity in adults.
    Yuen KC, Dunger DB.
    Diabetes Obes Metab; 2007 Jan; 9(1):11-22. PubMed ID: 17199714
    [Abstract] [Full Text] [Related]

  • 10. Metabolic impact of puberty on the course of type 1 diabetes.
    Acerini CL, Williams RM, Dunger DB.
    Diabetes Metab; 2001 Sep; 27(4 Pt 2):S19-25. PubMed ID: 11787432
    [Abstract] [Full Text] [Related]

  • 11. Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control.
    Chisalita SI, Lindström T, Eson Jennersjö P, Paulsson JF, Westermark GT, Olsson AG, Arnqvist HJ.
    Acta Diabetol; 2009 Mar; 46(1):35-42. PubMed ID: 18777156
    [Abstract] [Full Text] [Related]

  • 12. Insulin-like growth factor-I treatment of growth disorders, diabetes mellitus and insulin resistance.
    Ranke MB.
    Trends Endocrinol Metab; 2005 Mar; 16(4):190-7. PubMed ID: 15860416
    [Abstract] [Full Text] [Related]

  • 13. A general and islet cell-enriched overexpression of IGF-I results in normal islet cell growth, hypoglycemia, and significant resistance to experimental diabetes.
    Robertson K, Lu Y, De Jesus K, Li B, Su Q, Lund PK, Liu JL.
    Am J Physiol Endocrinol Metab; 2008 May; 294(5):E928-38. PubMed ID: 18270301
    [Abstract] [Full Text] [Related]

  • 14. Impact of treatment with recombinant human GH and IGF-I on visceral adipose tissue and glucose homeostasis in adults.
    Yuen KC, Dunger DB.
    Growth Horm IGF Res; 2006 Jul; 16 Suppl A():S55-61. PubMed ID: 16624605
    [Abstract] [Full Text] [Related]

  • 15. Characteristics of the somatotropic axis in insulin dependent diabetes mellitus.
    Mercado M, Baumann G.
    Arch Med Res; 1995 Jul; 26(2):101-9. PubMed ID: 7620273
    [Abstract] [Full Text] [Related]

  • 16. Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus.
    Pennisi P, Gavrilova O, Setser-Portas J, Jou W, Santopietro S, Clemmons D, Yakar S, LeRoith D.
    Endocrinology; 2006 Jun; 147(6):2619-30. PubMed ID: 16513827
    [Abstract] [Full Text] [Related]

  • 17. Heparin-induced modulation of insulin like-growth factor-I action on glucose level in control and fasted rats.
    Mnich Z, Pałka J.
    Med Sci Monit; 2001 Jun; 7(1):42-8. PubMed ID: 11208491
    [Abstract] [Full Text] [Related]

  • 18. Tissue-specific regulation of insulin-like growth factors and insulin-like growth factor binding proteins in male diabetic rats in vivo and in vitro.
    Han HJ, Kang CW, Park SH.
    Clin Exp Pharmacol Physiol; 2006 Dec; 33(12):1172-9. PubMed ID: 17184497
    [Abstract] [Full Text] [Related]

  • 19. Inverse changes in fetal insulin-like growth factor (IGF)-1 and IGF binding protein-1 in association with higher birth weight in maternal diabetes.
    Lindsay RS, Westgate JA, Beattie J, Pattison NS, Gamble G, Mildenhall LF, Breier BH, Johnstone FD.
    Clin Endocrinol (Oxf); 2007 Mar; 66(3):322-8. PubMed ID: 17302863
    [Abstract] [Full Text] [Related]

  • 20. Glucose disposal by insulin, but not IGF-1, is dependent on the hepatic parasympathetic nerves.
    Sadri P, Lautt WW.
    Can J Physiol Pharmacol; 2000 Oct; 78(10):807-12. PubMed ID: 11077981
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.